The Cape Town declaration on human papillomavirus related disease by Williamson, Anna-Lise et al.
Contents lists available at ScienceDirect
Papillomavirus Research
journal homepage: www.elsevier.com/locate/pvr
The Cape Town declaration on human papillomavirus related disease☆
In 2017, we already have the knowledge and experience to prevent much of the human papillomavirus (HPV)-related disease burden
globally. As a multidisciplinary research community, involving disciplines across the spectrum from basic science, epidemiology, vacci-
nology and screening to public health, we have provided much of the evidence base that has been translated into highly effective public
health programs around the world. Notably prophylactic HPV vaccination programs have already prevented HPV infections, genital warts
and cervical pre-cancers in many countries. HPV based screening programs now have strong evidence to support their use as a more sensitive
way to detect underlining cervical abnormalities, and we eagerly await the positive impacts of these emerging programs, which will be
applicable in both unvaccinated and vaccinated populations. There is an imperative, with the tools now available, to provide every woman
with access to effective cervical screening and every girl with access to prevention through vaccination. Access should be available irre-
spective of where a girl or woman lives, her social status or whether she is immunocompromised. HPV-related cancers also affect men, and
efforts to prevent HPV infection in men through HPV vaccination have the potential both to prevent many of these cancers and to reduce the
risk of HPV transmission to sexual partners. The International Papillomavirus Society (IPVS) believes all countries should consider and
promote national guidelines and programs to prevent HPV-related diseases, supported by international guidelines, access to international
expertise and support for implementation through increased access to more affordable vaccines and screening technology (e.g. through
revolving funds for vaccines). IPVS could be a bridge for these efforts.
As the HPV 2017 conference is in a region of the world with a very large burden of HPV-related disease, complicated by a large burden of HIV in
many countries, we call on governments to acknowledge both their current challenges and the immense opportunities to save lives by adopting the
tools we already know can work to prevent HPV and HPV-related cancers.
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